⚠ LIVE — European Consumer Safety Watch 💊 Medicinsk kanal: 18 Under de senaste 7 dagarna 🍎 kanal.mat.label: 180 Under de senaste 7 dagarna 🧸 Produkter i kanalen: 48 Under de senaste 7 dagarna 🟢 Övervakning: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Senaste hämtning: för 4 timmar sedan ⚠ LIVE — European Consumer Safety Watch 💊 Medicinsk kanal: 18 Under de senaste 7 dagarna 🍎 kanal.mat.label: 180 Under de senaste 7 dagarna 🧸 Produkter i kanalen: 48 Under de senaste 7 dagarna 🟢 Övervakning: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Senaste hämtning: för 4 timmar sedan
🛡️ EUSW
🇸🇪
💊

Ilaris

canakinumab
Cryopyrinassocierade periodiska syndrom;Artrit, juvenil reumatoid;Giktartrit
✅ Auktoriserad
Inga aktiva aviseringar
Denna medicin har inga pågående brister, säkerhetsbrev eller återkallelser.

Vad det används till

Periodic fever syndromes Ilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older: Cryopyrin-associated periodic syndromes Ilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including: Muckle-Wells syndrome (MWS), Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA), Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash. Tumour necrosis factor receptor associated periodic syndrome (TRAPS) Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS). Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD). Familial Mediterranean fever (FMF) Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate. Ilaris is also indicated for the treatment of: Still’s disease Ilaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate. Gouty arthritis Ilaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

⚠️ Patientsäkerhet

No

⚠️ Vi sammanställer officiella meddelanden. Vi lämnar ingen medicinsk rådgivning. För medicinska eller juridiska beslut, rådfråga den ansvariga myndigheten och en kvalificerad yrkesutövare.